公开(公告)号：EP3436591A1

公开(公告)日：2019-02-06

申请号：EP17715444.0

申请日：2017-03-31

申请人： The European Molecular Biology Laboratory ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

发明人： BERGER, Imre ,  GARZONI, Frédéric ,  FENDER, Pascal

IPC分类号： C12N15/86 ,  C07K14/005 ,  C12N7/00 ,  A61K39/12

公开(公告)号：EP1029070A1

公开(公告)日：2000-08-23

申请号：EP98952838.5

申请日：1998-11-03

申请人： COMMISSARIAT A L'ENERGIE ATOMIQUE ,  Centre National De La Recherche Scientifique-CNRS

发明人： CHROBOCZEK, Jadwiga ,  FENDER, Pascal

IPC分类号： C12N15/87 ,  C12N15/62 ,  C07K14/025 ,  C07K14/075 ,  A61K47/48 ,  A61K48/00

CPC分类号： C07K14/005 ,  A61K47/6901 ,  A61K48/00 ,  C07K2319/00 ,  C12N15/87 ,  C12N2710/10222 ,  C12N2710/10322

摘要： The invention concerns transfecting peptide vector, a composition containing said vector and their applications for treating and preventing diseases in human beings and animals. Said vector for transfecting a chemical substance selected in the group consisting of nucleic acid sequences, proteins, peptides and pharmacologically active substances, contains besides said chemical substance, at least a transfecting peptide derived entirely or partially from an adenovirus fibre and comprising at least a zone consisting of at least 50 % hydrophobic amino acids selected in the group consisting of alanine, valine, phenylamine, isoleucine, leucine, proline and methionine.

公开(公告)号：EP0861329A1

公开(公告)日：1998-09-02

申请号：EP96938303.0

申请日：1996-11-13

申请人： COMMISSARIAT A L'ENERGIE ATOMIQUE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

发明人： CHROBOCZEK, Jadwiga ,  FENDER, Pascal

IPC分类号： C12N15 ,  A61K31 ,  A61K35 ,  A61K48 ,  A61P43 ,  C07K14 ,  C12P21 ,  C12R1

CPC分类号： C07K14/005 ,  A61K48/00 ,  C12N2710/10222 ,  C12N2710/14143

摘要： A native or recombinant adenoviral protein complex, a pharmaceutical composition containing said protein complex, and the uses thereof for treating and preventing human and animal diseases, are disclosed. Said adenoviral protein complex consists of either 12 pentons each including at least one fibre and a penton base but no other element from an adenovirus genome, said fibre(s) and said penton base being derived from one or more adenoviruses, said pentons being bound by the penton bases and forming a proteolytic enzyme-stable dodecahedral structure, said complex having a molecular weight between 4.8 x 106 and 6.6 x 106, and such complexes being known as dodecahedron-penton complexes; or 12 penton bases but no other element from an adenovirus genome, said penton bases being derived from one or more adenoviruses and forming a proteolytic enzyme-stable dodecahedral structure, said complex having a molecular weight between 3.2 x 106 and 4 x 106, and such complexes being known as dodecahedron-base complexes.

公开(公告)号：EP4190906A1

公开(公告)日：2023-06-07

申请号：EP22216930.2

申请日：2017-03-31

申请人： The European Molecular Biology Laboratory ,  Centre National de la Recherche Scientifique

发明人： BERGER, Imre ,  GARZONI, Frédéric ,  FENDER, Pascal

IPC分类号： C12N15/86 ,  C07K14/005 ,  A61P37/02 ,  C12N7/00 ,  A61P35/00 ,  A61K39/12

摘要： The present invention relates to an engineered polypeptide comprising at least one adenovirus fibre protein N-terminal fragment specifically binding to an adenovirus fibre protein binding cleft of a penton base protomer and (i) a non-adenoviral peptide and/or (ii) is covalently or non-covalently coupled to a drug or label. The invention further relates to a VLP comprising the engineered polypeptide(s) of the invention bound to adenovirus fibre protein binding cleft of adenovirus penton base protomers forming the VLP. Further subject matter of the invention are nucleic acids and vectors for cloning and expression of the engineered polypeptide. The invention also relates to methods for producing the engineered polypeptide and the VLP. The engineered polypeptide and the VLP are useful in the treatment or prevention of infectious diseases, immune diseases and cancer.